Summary
Global Markets Direct’s, ‘Yellow Fever - Pipeline Review, H1 2016’, provides an overview of the Yellow Fever pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Yellow Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Yellow Fever
- The report reviews pipeline therapeutics for Yellow Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Yellow Fever therapeutics and enlists all their major and minor projects
- The report assesses Yellow Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Yellow Fever
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Yellow Fever
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Yellow Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Adamas Pharmaceuticals, Inc.
Arno Therapeutics, Inc.
BioCryst Pharmaceuticals, Inc.
iBio, Inc.
Johnson & Johnson
NewLink Genetics Corporation
Panacea Biotec Limited
Sihuan Pharmaceutical Holdings Group Ltd.
Themis Bioscience GmbH
Valneva SE
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Yellow Fever Overview 8
Therapeutics Development 9
Pipeline Products for Yellow Fever - Overview 9
Pipeline Products for Yellow Fever - Comparative Analysis 10
Yellow Fever - Therapeutics under Development by Companies 11
Yellow Fever - Therapeutics under Investigation by Universities/Institutes 12
Yellow Fever - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Yellow Fever - Products under Development by Companies 15
Yellow Fever - Products under Investigation by Universities/Institutes 16
Yellow Fever - Companies Involved in Therapeutics Development 17
Adamas Pharmaceuticals, Inc. 17
Arno Therapeutics, Inc. 18
BioCryst Pharmaceuticals, Inc. 19
iBio, Inc. 20
Johnson & Johnson 21
NewLink Genetics Corporation 22
Panacea Biotec Limited 23
Sihuan Pharmaceutical Holdings Group Ltd. 24
Themis Bioscience GmbH 25
Valneva SE 26
Yellow Fever - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
(arenavirus + yellow fever) vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ADS-324 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AR-12 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BCX-4430 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
DEF-201 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
DiTU - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
FDX-000 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
JK-05 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
LCTA-949 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
yellow fever [strain YF17D] vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
yellow fever vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
yellow fever vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
yellow fever vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
yellow fever vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
yellow fever vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
yellow fever vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
yellow fever vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Yellow Fever - Recent Pipeline Updates 59
Yellow Fever - Dormant Projects 64
Yellow Fever - Product Development Milestones 65
Featured News & Press Releases 65
Sep 14, 2010: Themis Bioscience And Institut Pasteur Form R&D Alliance To Fight Tropical Infectious Diseases Including Yellow Fever. 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67
List of Tables
Number of Products under Development for Yellow Fever, H1 2016 9
Number of Products under Development for Yellow Fever - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Yellow Fever - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016 17
Yellow Fever - Pipeline by Arno Therapeutics, Inc., H1 2016 18
Yellow Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H1 2016 19
Yellow Fever - Pipeline by iBio, Inc., H1 2016 20
Yellow Fever - Pipeline by Johnson & Johnson, H1 2016 21
Yellow Fever - Pipeline by NewLink Genetics Corporation, H1 2016 22
Yellow Fever - Pipeline by Panacea Biotec Limited, H1 2016 23
Yellow Fever - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 24
Yellow Fever - Pipeline by Themis Bioscience GmbH, H1 2016 25
Yellow Fever - Pipeline by Valneva SE, H1 2016 26
Assessment by Monotherapy Products, H1 2016 27
Assessment by Combination Products, H1 2016 28
Number of Products by Stage and Target, H1 2016 30
Number of Products by Stage and Mechanism of Action, H1 2016 32
Number of Products by Stage and Route of Administration, H1 2016 34
Number of Products by Stage and Molecule Type, H1 2016 36
Yellow Fever Therapeutics - Recent Pipeline Updates, H1 2016 59
Yellow Fever - Dormant Projects, H1 2016 64
List of Figures
Number of Products under Development for Yellow Fever, H1 2016 9
Number of Products under Development for Yellow Fever - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Top 10 Targets, H1 2016 29
Number of Products by Stage and Top 10 Targets, H1 2016 29
Number of Products by Top 10 Mechanism of Actions, H1 2016 31
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 31
Number of Products by Routes of Administration, H1 2016 33
Number of Products by Stage and Routes of Administration, H1 2016 33
Number of Products by Molecule Types, H1 2016 35
Number of Products by Stage and Molecule Types, H1 2016 35
